A small-molecule inhibitor of D-cyclin transactivation displays preclinical efficacy in myeloma and leukemia via phosphoinositide 3-kinase pathway

Blood

Volumn 117, Issue 6, 2011, Pages 1986-1997

  Mao, Xinliang ^a,b   Cao, Biyin ^a   Wood, Tabitha E ^b,c   Hurren, Rose ^b   Tong, Jiefei ^d   Wang, Xiaoming ^b   Wang, Wenjie ^a   Li, Jie ^a   Jin, Yueping ^a   Sun, Wenxian ^a   Spagnuolo, Paul A ^b   MacLean, Neil ^b   Moran, Michael F ^c,d   Datti, Alessandro ^e,f   Wrana, Jeffery ^c,e   Batey, Robert A ^c   Schimmer, Aaron D ^b,c  

^a SOOCHOW UNIVERSITY   (China)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e MOUNT SINAI HOSPITAL   (Canada)

^f UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

8 ETHOXY 2 (4 FLUOROPHENYL) 3 NITRO 2H CHROMENE; CHROMENE DERIVATIVE; CYCLIN D1; CYCLIN D2; CYCLIN D3; DNA DEPENDENT PROTEIN KINASE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B; S 14161; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL LINE; MOUSE; MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSACTIVATION; WEIGHT REDUCTION;

EID: 79951474743     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-05-284810     Document Type: Article

References (40)

1. Sherr CJ. Cancer cell cycles. Science. 1996; 274(5293):1672-1677.
2. Ely S, Di Liberto M, Niesvizky R, et al. Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma. Cancer Res. 2005;65(24):11345-11353. (Pubitemid 41821691)
3. Sasaki Y, Jensen CT, Karlsson S, Jacobsen SE. Enforced expression of cyclin D2 enhances the proliferative potential of myeloid progenitors, accelerates in vivo myeloid reconstitution, and promotes rescue of mice from lethal myeloablation. Blood. 2004;104(4):986-992. (Pubitemid 39038017)
4. Yata K, Sadahira Y, Otsuki T, et al. Cell cycle analysis and expression of cell cycle regulator genes in myeloma cells overexpressing cyclin D1. Br J Haematol. 2001;114(3):591-599. (Pubitemid 32953637)
5. Hochhauser D, Schnieders B, Ercikan-Abali E, et al. Effect of cyclin D1 overexpression on drug sensitivity in a human fibrosarcoma cell line. J Natl Cancer Inst. 1996;88(18):1269-1275. (Pubitemid 26301614)
6. Sarfaraz S, Afaq F, Adhami VM, Malik A, Mukhtar H. Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G1 cell cycle arrest. J Biol Chem. 2006;281(51): 39480-39491. (Pubitemid 46041908)
7. Baughn LB, Di Liberto M, Wu K, et al. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res. 2006;66(15): 7661-7667. (Pubitemid 44289224)
8. Mantena SK, Sharma SD, Katiyar SK. Berberine inhibits growth, induces G1 arrest and apoptosis in human epidermoid carcinoma A431 cells by regulating Cdki-Cdk-cyclin cascade, disruption of mitochondrial membrane potential and cleavage of caspase 3 and PARP. Carcinogenesis. 2006; 27(10):2018-2027. (Pubitemid 44530576)
9. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood. 2005;106(1):296-303. (Pubitemid 40967205)
10. Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 2004;350(16): 1617-1628. (Pubitemid 38528701)
11. Hanamura I, Huang Y, Zhan F, Barlogie B, Shaughnessy J. Prognostic value of cyclin D2 mRNA expression in newly diagnosed multiple myeloma treated with high-dose chemotherapy and tandem autologous stem cell transplantations. Leukemia. 2006;20(7):1288-1290. (Pubitemid 43905833)
12. Mao X, Stewart AK, Hurren R, et al. A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin. Blood. 2007;110(12):4047-4054. (Pubitemid 350248461)
13. Mao X, Zhu X, Hurren R, Ezzat S, Schimmer AD. Dexamethasone increases ubiquitin transcription through an SP-1 dependent mechanism in multiple myeloma cells. Leuk Res. 2008;32(9):1480-1482.
14. Mao X, Liang SB, Hurren R, et al. Cyproheptadine displays preclinical activity in myeloma and leukemia. Blood. 2008;112(3):760-769.
15. Tiedemann RE, Mao X, Shi CX, et al. Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity. J Clin Invest. 2008;118(5):1750-1764. (Pubitemid 351632378)
16. Carter BZ, Gronda M, Wang Z, et al. Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells. Blood. 2005;105(10):4043-4050. (Pubitemid 40656154)
17. Carlson B, Lahusen T, Singh S, et al. Downregulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res. 1999;59(18): 4634-4641.
18. Chen R, Chubb S, Cheng T, Hawtin RE, Gandhi V, Plunkett W. Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line. Cancer Res. 2010;70(16): 6587-6597.
19. White PC, Shore AM, Clement M, et al. Regulation of cyclin D2 and the cyclin D2 promoter by protein kinase A and CREB in lymphocytes. Oncogene. 2006;25(15):2170-2180.
20. Brennan P, Mehl AM, Jones M, Rowe M. Phosphatidylinositol 3-kinase is essential for the proliferation of lymphoblastoid cells. Oncogene. 2002; 21(8):1263-1271. (Pubitemid 34185243)
21. Georgakis GV, Li Y, Rassidakis GZ, Medeiros LJ, Mills GB, Younes A. Inhibition of the phosphatidylinositol-3 kinase/AKT promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma. Br J Haematol. 2006;132(4):503-511. (Pubitemid 43381621)
22. Zollinger A, Stuhmer T, Chatterjee M, et al. Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: AKT-dependent and AKT-independent multiple myeloma. Blood. 2008;112(8):3403- 3411.
23. Chan TO, Tsichlis PN. PDK2: a complex tail in one AKT. Sci STKE. 2001;2001(66):pe1.
24. Harris TK. PDK1 and PKB/AKT: ideal targets for development of new strategies to structure-based drug design. IUBMB Life. 2003;55(3):117-126. (Pubitemid 36702655)
25. Meier R, Thelen M, Hemmings BA. Inactivation and dephosphorylation of protein kinase Balpha (PKBalpha) promoted by hyperosmotic stress. EMBO J. 1998;17(24):7294-7303. (Pubitemid 29002698)
26. Zhang C, Yang N, Yang CH, et al. S9, a novel anticancer agent, exerts its anti-proliferative activity by interfering with both PI3K-AKT-mTOR signaling and microtubule cytoskeleton. PLoS ONE. 2009;4(3):e4881.
27. Steeg PS, Zhou Q. Cyclins and breast cancer. Breast Cancer Res Treat. 1998;52(1-3):17-28. (Pubitemid 29056082)
28. Toualbi-Abed K, Daniel F, Guller MC, et al. Jun D cooperates with p65 to activate the proximal kappaB site of the cyclin D1 promoter: role of PI3K/PDK-1. Carcinogenesis. 2008;29(3):536-543. (Pubitemid 351404869)
29. Chang H, Qi XY, Claudio J, Zhuang L, Patterson B, Stewart AK. Analysis of PTEN deletions and mutations in multiple myeloma. Leuk Res. 2006;30(3): 262-265. (Pubitemid 43053219)
30. Adati N, Huang MC, Suzuki T, Suzuki H, Kojima T. High-resolution analysis of aberrant regions in autosomal chromosomes in human leukemia THP-1 cell line. BMC Res Notes. 2009;2:153.
31. Kawauchi K, Ogasawara T, Yasuyama M, Otsuka K, Yamada O. The PI3K/AKT pathway as a target in the treatment of hematologic malignancies. Anticancer Agents Med Chem. 2009;9(5):550-559.
32. Schmelz K, Sattler N, Wagner M, Lubbert M, Dorken B, Tamm I. Induction of gene expression by 5-Aza-2′-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms. Leukemia. 2005;19(1):103-111. (Pubitemid 40090084)
33. Chandras C, Koutmani Y, Kokkotou E, Pothoulakis C, Karalis KP. Activation of phosphatidylinositol 3-kinase/protein kinase B by corticotropin-releasing factor in human monocytes. Endocrinology. 2009;150(10):4606-4614.
34. Billottet C, Banerjee L, Vanhaesebroeck B, Khwaja A. Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation. Cancer Res. 2009;69(3):1027-1036.
35. Silva A, Yunes JA, Cardoso BA, et al. PTEN post-translational inactivation and hyperactivation of the PI3K/AKT pathway sustain primary T cell leukemia viability. J Clin Invest. 2008;118(11):3762-3774.
36. Chiarini F, Fala F, Tazzari PL, et al. Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. Cancer Res. 2009;69(8):3520-3528.
37. Steelman LS, Abrams SL, Whelan J, et al. Contributions of the Raf/MEK/ERK, PI3K/PTEN/AKT/mTOR and Jak/STAT pathways to leukemia. Leukemia. 2008;22(4):686-707. (Pubitemid 351565618)
38. Min YH, Eom JI, Cheong JW, et al. Constitutive phosphorylation of AKT/PKB protein in acute myeloid leukemia: its significance as a prognostic variable. Leukemia. 2003;17(5):995-997. (Pubitemid 36626336)
39. Grandage VL, Gale RE, Linch DC, Khwaja A. PI3-kinase/AKT is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia. 2005;19(4): 586-594. (Pubitemid 40521164)
40. Hu L, Zaloudek C, Mills GB, Gray J, Jaffe RB. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res. 2000;6(3):880-886. (Pubitemid 30159344)